✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹550 Cr.
P/E
30.71
About
Zim Laboratories Ltd has established itself as one of the preferred healthcare solution providers in the field of New Drug Delivery Systems (NDDS). The company has pioneered several innovative techn… Read more
Zim Laboratories Ltd has established itself as one of the preferred healthcare solution provi… Read more
Low
90
52W Range
High
131
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Custom financial statement
Edit rows
Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

9 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Customer Segment

Capex

Asset Break-Up

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Customers
    • Gufic Biosciences Ltd.
    • RPG Life Sciences Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Alkem Laboratories Ltd.
    • Mankind Pharma
    FAQs on Zim Laboratories Ltd. Business

    Zim Laboratories Ltd is a leading healthcare solution provider specializing in New Drug Delivery Systems. They have developed innovative technologies and products in areas such as Pellets, Multiplets, Resinates, Herbals, and Diagnostics.

    Zim Laboratories major competitors are Lyka Labs, Kilitch Drugs(India), Medicamen Biotech, Gennex Lab, Jenburkt Pharma, Ambalal Sarabhai Ent, Balaxi Pharma..
    Market Cap of Zim Laboratories is ₹550 Crs.
    While the median market cap of its peers are ₹588 Crs.

    Zim Laboratories seems to be less financially stable compared to its competitors.
    Altman Z score of Zim Laboratories is 3.34 and is ranked 8 out of its 8 competitors.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Jun Mar Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis